Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • NCI-CCC Breast Tumor Board Question • Breast Cancer, Metastatic
In light of SABCS 2022, when will you opt for a CDK 4/6 inhibitor plus AI instead of chemotherapy in patients with metastatic HR-positive HER2-negative breast cancer with visceral crisis?
Answer from: Medical Oncologist at Academic Institution
I think it is very reassuring to see that ribociclib + ET led to similar (or better) overall response rates than combination chemotherapy in the RIGHT choice trial presented at SABCS 2022. However, it is incredibly important to keep in mind that the definition of "impending visceral compromise" or "...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I will certainly consider it a lot more than prior to these results. I would still favor doublet chemotherapy in cases where rapid response is necessary to avoid impending life-threatening crises since endocrine therapy has a delayed onset of action.
Comments
Medical Oncologist at Tripler Army Medical Center
Will defer chemo.
Will defer chemo.
Answer from: Medical Oncologist at Community Practice
Responses to CDK4/6 inhibitors are fairly rapid. I have been using abemaciclib with an AI in a neoadjuvant setting and have seen significant shrinkage of tumors in 2-3 weeks. Similarly, in metastatic disease, responses are fairly rapid. So in the metastatic setting, I would use a CDK4/6 inhibitor un...
Comments
Medical Oncologist at Pacific Cancer Care
Is this on trial? How do you get it approved with ...
Is this on trial? How do you get it approved with ...
Medical Oncologist at Fort Sutter Med Onc/Hem
The RIGHT Choice trial just presented at SABCS.
The RIGHT Choice trial just presented at SABCS.